Skip to main content
Top
Published in: Rheumatology International 9/2012

01-09-2012 | Original Article

Is it safe to use anti-TNF-α agents for tuberculosis in children suffering with chronic rheumatic disease?

Authors: Omer Kilic, Ozgur Kasapcopur, Yildiz Camcioglu, Haluk Cokugras, Nil Arisoy, Necla Akcakaya

Published in: Rheumatology International | Issue 9/2012

Login to get access

Abstract

To determine the incidence of latent tuberculosis infection and evaluate the follow-up protocol of the patients diagnosed with juvenile idiopathic arthritis (JIA) and other chronic rheumatologic diseases treated with anti-TNF-α treatment (etanercept, infliximab, adalimumab) in Turkey, 144 patients were evaluated retrospectively for the development of tuberculosis. Patients were evaluated every 6 months for tuberculosis using history, physical examination, tuberculin skin test (TST), chest radiographs, and, when required, examination of sputum/early morning gastric aspirates for acid-fast bacilli and chest tomography. A tuberculin skin test over 10 mm induration was interpreted as positive. Patients were diagnosed with JIA (n = 132), enthesitis-related arthritis (ERA; n = 14), juvenile psoriatic arthritis (JPsA; n = 4), chronic idiopathic uveitis (n = 4), and chronic arthritis related to FMF (n = 8). Mean age was 12.25 ± 3.96 years (4.08–19.41 years), mean duration of illness was 5.86 ± 3.77 years (0.66–15 years), and the mean duration of anti-TNF-α treatment was 2.41 ± 1.47 years (0.6–7 years). Anti-TNF-α agents prescribed were etanercept (n = 133), infliximab (n = 30), and adalimumab (n = 6). When unresponsive to one anti-TNF-α therapy, patients were switched to another. There was no history of contact with individuals having tuberculosis. During follow-up, seven patients (4.8%) with positive TST were given INH prophylaxis. One oligoarticular JIA patient (0.69%) diagnosed with secondary uveitis who had been followed for 5 years and had been using infliximab for 2 years, developed a positive Quantiferon-TB test while on INH prophylaxis. He was started on an anti-tuberculosis drug regimen. In conclusion, anti-TNF-α treatment in children with chronic inflammatory disease is safe. Follow-up every 6 months of children on anti-TNF-α treatment with respect to tuberculosis by the pediatric infectious disease department is important to prevent possible complications.
Literature
1.
2.
go back to reference Beresford MW, Baildam EM (2009) New advances in the management of juvenile idiopathic arthritis-2: the era of biologicals. Arch Dis Child Educ Pract Ed 94:151–156PubMedCrossRef Beresford MW, Baildam EM (2009) New advances in the management of juvenile idiopathic arthritis-2: the era of biologicals. Arch Dis Child Educ Pract Ed 94:151–156PubMedCrossRef
3.
go back to reference WHO Report (2007) Global tuberculosis control: surveillance, planning, financing. WHO, Geneva WHO Report (2007) Global tuberculosis control: surveillance, planning, financing. WHO, Geneva
4.
go back to reference Sester U, Junker H, Hodapp T, Schütz A, Thiele B, Meyerhans A et al (2006) Improved efficiency in detecting cellular immunity towards M. tuberculosis in patients receiving immunosuppressive drug therapy. Nephrol Dial Transpl 21:3258–3268CrossRef Sester U, Junker H, Hodapp T, Schütz A, Thiele B, Meyerhans A et al (2006) Improved efficiency in detecting cellular immunity towards M. tuberculosis in patients receiving immunosuppressive drug therapy. Nephrol Dial Transpl 21:3258–3268CrossRef
5.
go back to reference Arend WP (2001) Physiology of cytokine pathways in rheumatoid arthritis. Arthr Rheum 45:101–106CrossRef Arend WP (2001) Physiology of cytokine pathways in rheumatoid arthritis. Arthr Rheum 45:101–106CrossRef
6.
go back to reference Crum NF, Lederman ER, Wallace MR (2005) Infections associated with tumor necrosis factor-α antagonists. Medicine (Baltimore) 84:291–302CrossRef Crum NF, Lederman ER, Wallace MR (2005) Infections associated with tumor necrosis factor-α antagonists. Medicine (Baltimore) 84:291–302CrossRef
7.
go back to reference Gómez-Reino JJ, Carmona L, Valverde VR, Mola EM, Montero MD, BIOBADASER Group (2003) Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. Arthr Rheum 48:2122–2127CrossRef Gómez-Reino JJ, Carmona L, Valverde VR, Mola EM, Montero MD, BIOBADASER Group (2003) Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. Arthr Rheum 48:2122–2127CrossRef
8.
go back to reference Wallis RS, Broder MS, Wong JY, Hanson ME, Beenhouwer DO (2004) Granulomatous infectious diseases associated with tumor necrosis factor antagonists. Clin Infect Dis 38:1261–1265PubMedCrossRef Wallis RS, Broder MS, Wong JY, Hanson ME, Beenhouwer DO (2004) Granulomatous infectious diseases associated with tumor necrosis factor antagonists. Clin Infect Dis 38:1261–1265PubMedCrossRef
9.
go back to reference Long R, Gardam M (2003) Tumour necrosis factor-α inhibitors and the reactivation of latent tuberculosis infection. CMAJ 168:1153–1156PubMed Long R, Gardam M (2003) Tumour necrosis factor-α inhibitors and the reactivation of latent tuberculosis infection. CMAJ 168:1153–1156PubMed
10.
go back to reference Wallis RS, Broder M, Wong J, Beenhouwer D (2004) Granulomatous infections due to tumor necrosis factor blockade: correction. Clin Infect Dis 39:1254–1255PubMedCrossRef Wallis RS, Broder M, Wong J, Beenhouwer D (2004) Granulomatous infections due to tumor necrosis factor blockade: correction. Clin Infect Dis 39:1254–1255PubMedCrossRef
11.
go back to reference Tubach F, Salmon-Céron D, Ravaud P, Mariette X (2005) The RATIO observatory: French registry of opportunistic infections, severe bacterial infections, and lymphomas complicating anti-TNF alpha therapy. Joint Bone Spine 72:456–460PubMedCrossRef Tubach F, Salmon-Céron D, Ravaud P, Mariette X (2005) The RATIO observatory: French registry of opportunistic infections, severe bacterial infections, and lymphomas complicating anti-TNF alpha therapy. Joint Bone Spine 72:456–460PubMedCrossRef
12.
go back to reference Saliu OY, Sofer C, Stein DS, Schwander SK, Wallis RS (2006) Tumor-necrosis-factor blockers: differential effects on mycobacterial immunity. J Infect Dis 194:486–492PubMedCrossRef Saliu OY, Sofer C, Stein DS, Schwander SK, Wallis RS (2006) Tumor-necrosis-factor blockers: differential effects on mycobacterial immunity. J Infect Dis 194:486–492PubMedCrossRef
13.
go back to reference Carmona L, Gómez-Reino JJ, Rodríguez-Valverde V, Montero D, Pascual-Gómez E, Mola EM et al (2005) Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists. Arthr Rheum 52:1766–1772CrossRef Carmona L, Gómez-Reino JJ, Rodríguez-Valverde V, Montero D, Pascual-Gómez E, Mola EM et al (2005) Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists. Arthr Rheum 52:1766–1772CrossRef
14.
go back to reference Cagatay T, Aydın M, Sunmez S, Cagatay P, Gulbaran Z, Gul A et al (2010) Follow-up results of 702 patients receiving tumor necrosis factor-alpha antagonists and evaluation of risk of tuberculosis. Rheumatol Int 30:1459–1463PubMedCrossRef Cagatay T, Aydın M, Sunmez S, Cagatay P, Gulbaran Z, Gul A et al (2010) Follow-up results of 702 patients receiving tumor necrosis factor-alpha antagonists and evaluation of risk of tuberculosis. Rheumatol Int 30:1459–1463PubMedCrossRef
15.
go back to reference Winthrop KL, Seigel JN, Jereb J, Taylor Z, Iademarco MF (2005) TB associated with therapy against tumor necrosis factor α. Arthr Rheum 52:2968–2974CrossRef Winthrop KL, Seigel JN, Jereb J, Taylor Z, Iademarco MF (2005) TB associated with therapy against tumor necrosis factor α. Arthr Rheum 52:2968–2974CrossRef
16.
go back to reference Yokota S, Mori M, Imagawa T, Murata T, Tomiita M, Itoh Y et al (2010) Guidelines on the use of etanercept for juvenile idiopathic arthritis in Japan. Mod Rheumatol 20:107–113PubMedCrossRef Yokota S, Mori M, Imagawa T, Murata T, Tomiita M, Itoh Y et al (2010) Guidelines on the use of etanercept for juvenile idiopathic arthritis in Japan. Mod Rheumatol 20:107–113PubMedCrossRef
17.
go back to reference Mariette X, Salmon D (2003) French guidelines for diagnosis and treating latent and active tuberculosis in patients with RA treated with TNF blockers. Ann Rheum Dis 62:791PubMedCrossRef Mariette X, Salmon D (2003) French guidelines for diagnosis and treating latent and active tuberculosis in patients with RA treated with TNF blockers. Ann Rheum Dis 62:791PubMedCrossRef
18.
go back to reference British Thoracic Society Standards of Care Committee (2005) BTS recommendations for assessing risk and for managing Mycobactcerium tuberculosis infection and disease in patients due to start anti-TNF-alpha treatment. Thorax 60:800–805CrossRef British Thoracic Society Standards of Care Committee (2005) BTS recommendations for assessing risk and for managing Mycobactcerium tuberculosis infection and disease in patients due to start anti-TNF-alpha treatment. Thorax 60:800–805CrossRef
19.
go back to reference American Thoracic Society (2000) Targeted tuberculin testing and treatment of latent tuberculosis infection. Am J Respir Crit Care Med 161:221–247 American Thoracic Society (2000) Targeted tuberculin testing and treatment of latent tuberculosis infection. Am J Respir Crit Care Med 161:221–247
20.
go back to reference Beglinger C, Dudler J, Mottet C, Nicod L, Seibold F, Villiger PM et al (2007) Screening for tuberculosis infection before the initiation of an anti-TNF-alpha therapy. Swiss Med Wkly 137:620–622PubMed Beglinger C, Dudler J, Mottet C, Nicod L, Seibold F, Villiger PM et al (2007) Screening for tuberculosis infection before the initiation of an anti-TNF-alpha therapy. Swiss Med Wkly 137:620–622PubMed
21.
go back to reference Vukmanovic-Stejic M, Reed JR, Lacy KE, Rustin MH, Akbar AN (2006) Mantoux test as a model for a secondary immune response in humans. Immunol Lett 107:93–101PubMedCrossRef Vukmanovic-Stejic M, Reed JR, Lacy KE, Rustin MH, Akbar AN (2006) Mantoux test as a model for a secondary immune response in humans. Immunol Lett 107:93–101PubMedCrossRef
22.
go back to reference Kiray E, Kasapcopur O, Bas V, Kamburoglu-Goksel A, Midilli K, Arisoy N et al (2009) Purified protein derivative response in juvenile idiopathic arthritis. J Rheumatol 36:2029–2032PubMedCrossRef Kiray E, Kasapcopur O, Bas V, Kamburoglu-Goksel A, Midilli K, Arisoy N et al (2009) Purified protein derivative response in juvenile idiopathic arthritis. J Rheumatol 36:2029–2032PubMedCrossRef
23.
go back to reference Ayaz NA, Demirkaya E, Bilginer Y, Ozcelik U, Cobanoglu N, Kiper N et al (2010) Preventing tuberculosis in children receiving anti-TNF treatment. Clin Rheumatol 29:389–392PubMedCrossRef Ayaz NA, Demirkaya E, Bilginer Y, Ozcelik U, Cobanoglu N, Kiper N et al (2010) Preventing tuberculosis in children receiving anti-TNF treatment. Clin Rheumatol 29:389–392PubMedCrossRef
24.
go back to reference Cagatay T, Kilicaslan Z, Cagatay P, Mertsoylu M, Gulbaran Z, Yildiz R et al (2010) TNF-alpha antagonist therapy modify the tuberculin skin test response. Rheumatol Int Mar 27 (Epub ahead of print) Cagatay T, Kilicaslan Z, Cagatay P, Mertsoylu M, Gulbaran Z, Yildiz R et al (2010) TNF-alpha antagonist therapy modify the tuberculin skin test response. Rheumatol Int Mar 27 (Epub ahead of print)
Metadata
Title
Is it safe to use anti-TNF-α agents for tuberculosis in children suffering with chronic rheumatic disease?
Authors
Omer Kilic
Ozgur Kasapcopur
Yildiz Camcioglu
Haluk Cokugras
Nil Arisoy
Necla Akcakaya
Publication date
01-09-2012
Publisher
Springer-Verlag
Published in
Rheumatology International / Issue 9/2012
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-011-2030-8

Other articles of this Issue 9/2012

Rheumatology International 9/2012 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.